Coronado nabs preclinical cancer assets from NeuPharma
This article was originally published in Scrip
After a restructuring of the company a little more than a year ago, Coronado Biosciences is continuing to add to its pipeline portfolio – the biotech struck a deal with NeuPharma on 19 March for an undisclosed number of preclinical cancer assets. Coronado agreed to pay an undisclosed up front fee, as well as development- and sales-based milestones. Coronado also agreed to single-digit sales royalties on any products that result. The biotech will develop and commercialize irreversible, third-generation epidermal growth factor receptor (EGRF) inhibitors worldwide, except for Asian countries. The deal comes about a year after Coronado's lead therapy – a treatment for Crohn's disease developed using parasitic worms – failed in Phase II trials to show any effectiveness beyond a placebo (scripintelligence.com, 14 October 2013). The clinical trial failure forced Coronado to pare down the company (scripintelligence.com, 08 November 2013).
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.